Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurothera LabsFRA:C0A0 23 EV-to-EBITDA is -235.52 as of Sep. 07, 2026. GuruFocus rates FRA:C0A0 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 726 Drug Manufacturers companies, Neurothera Labs ranks worse than 137740.91% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Neurothera Labs's enterprise value is €29.20 Mil.
Neurothera Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.12 Mil. Therefore, Neurothera Labs's EV-to-EBITDA for today is -235.52.
The historical rank and industry rank for Neurothera Labs's EV-to-EBITDA or its related term are showing as below:
FRA:C0A0'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -250.44 Med: 0 Max: 0
Current: -250.44
FRA:C0A0's EV-to-EBITDA is ranked worse than 100% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.56
vs FRA:C0A0: -250.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neurothera Labs's PE Ratio (TTM) for today is calculated as:
Neurothera Labs's share price for today is €0.85.
Neurothera Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.063.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Neurothera Labs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:C0A0 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Neurothera Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurothera Labs EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Neurothera Labs's EV-to-EBITDA falls into.
Neurothera Labs's current Enterprise Value is €29.20 Mil.
Neurothera Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurothera Labs (FRA:C0A0) has a EV-to-EBITDA of -235.52 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neurothera Labs. According to the industry distribution chart, Neurothera Labs ranks #999999 out of 726 companies in the Drug Manufacturers industry.
Is Neurothera Labs' EV-to-EBITDA too high?
Neurothera Labs' current EV-to-EBITDA is -235.52. Based on the distribution chart, Neurothera Labs ranks #999999 out of 726 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurothera Labs has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Neurothera Labs ranks #999999 out of 726 companies for EV-to-EBITDA. This places Neurothera Labs in the lower half of its industry. The industry median EV-to-EBITDA is 13.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.56, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neurothera Labs. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurothera Labs's current EV-to-EBITDA is -235.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (FRA:C0A0) has a current EV-to-EBITDA of -235.52. The current EV-to-EBITDA is -235.52. Neurothera Labs' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Neurothera Labs (FRA:C0A0), the current EV-to-EBITDA is -235.52 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
23GF Score
Get the complete analysis for FRA:C0A0
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C0A0 has been successfully added to your 
